Equities

KPC Pharmaceuticals Inc

600422:SHH

KPC Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)14.70
  • Today's Change0.24 / 1.66%
  • Shares traded9.73m
  • 1 Year change-32.13%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.

  • Revenue in CNY (TTM)7.55bn
  • Net income in CNY446.07m
  • Incorporated1995
  • Employees5.05k
  • Location
    KPC Pharmaceuticals IncNo. 166Keyi Road, High-tech Development ZoneKUNMING 650106ChinaCHN
  • Phone+86 87 168324311
  • Fax+86 87 168324267
  • Websitehttp://www.kpc.com.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Changchun BCHT Biotechnology Co1.61bn414.29m10.71bn1.24k25.872.55--6.661.001.003.8810.150.31811.001.061,295,333.008.209.9510.2312.8187.5586.6325.7724.031.85--0.014710.5570.3012.36175.9831.3721.04--
Cansino Biologics Inc748.53m-720.11m10.72bn1.49k--3.12--14.33-2.92-2.923.0320.460.08510.63411.12501,023.80-8.41-4.27-11.09-5.5967.7141.73-98.82-27.602.27-8.750.2934---65.49163.48-63.04--30.60--
Mayinglong Pharmaceutical Group Co Ltd3.48bn482.37m10.82bn2.88k22.422.70--3.111.121.128.089.280.68726.428.531,208,299.009.7410.8211.6413.4744.8441.1814.1714.084.40--0.093633.04-11.207.38-7.4620.2658.3321.67
Heilongjiang ZBD Pharmaceutical Co Ltd2.58bn114.60m10.92bn2.55k97.091.41--4.230.11940.11942.748.240.21181.480.76451,014,704.000.88223.481.174.7834.5238.934.1710.082.23--0.288827.18-25.502.45155.000.4417-25.684.05
KPC Pharmaceuticals Inc7.55bn446.07m11.13bn5.05k24.822.01--1.470.59240.592410.037.310.78192.752.561,494,697.004.645.427.759.1340.8443.685.945.701.51--0.17235.75-6.991.6416.055.79-21.3314.87
Liaoning Chengda Biotechnology Co Ltd1.72bn332.10m11.18bn1.73k33.431.17--6.510.80320.80324.1622.930.17020.7631.43991,973.803.2910.633.4111.0180.5385.7419.3339.5617.44--0.001831.53-3.584.71-34.75-5.5639.78--
Tibet Rhodiola Pharmaceutical Holding Co2.94bn737.44m11.73bn601.0014.113.23--3.992.582.589.6911.260.62641.546.794,894,779.0015.8012.4420.8315.7193.3690.5125.2220.433.447.740.126450.4122.6924.98116.5630.01-1.4848.97
Jiangxi Tianxin Pharmaceutical Co Ltd2.01bn557.43m11.78bn2.47k21.152.64--5.871.271.274.5810.180.39772.7510.26812,720.6011.04--11.82--41.64--27.76--6.39--0.0234---18.34---23.51------
Henan Lingrui Pharmaceutical Co., Ltd.3.56bn675.80m11.81bn2.53k17.344.08--3.311.201.206.345.100.74892.2410.181,408,620.0014.2010.6823.5216.5672.3574.4218.9614.920.9579--0.007372.8010.3110.0322.0918.49-16.4739.77
Data as of Nov 25 2024. Currency figures normalised to KPC Pharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

19.98%Per cent of shares held by top holders
HolderShares% Held
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202472.91m9.63%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 202424.68m3.26%
GF Fund Management Co., Ltd.as of 30 Jun 202412.66m1.67%
China Investment Corp. (Investment Management)as of 30 Sep 202311.81m1.56%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 202411.30m1.49%
UBS SDIC Fund Management Co., Ltd.as of 30 Jun 20247.19m0.95%
Penghua Fund Management Co., Ltd.as of 30 Jun 20243.70m0.49%
Orient Securities Asset Management Co. Ltd.as of 30 Jun 20242.38m0.32%
China Universal Asset Management Co., Ltd.as of 30 Jun 20242.33m0.31%
First Seafront Fund Management Co., Ltd.as of 30 Jun 20242.25m0.30%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.